公开(公告)号：US11186635B2

公开(公告)日：2021-11-30

申请号：US16343889

申请日：2017-10-25

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PARIS DIDEROT—PARIS 7 ,  UNIVERSITÉ DE MONTPELLIER ,  INSTITUT JEAN GODINOT ,  INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER

Inventor： Armand Bensussan ,  Bruno Robert ,  Pierre Martineau ,  Myriam Chentouf ,  Anne Marie-Cardine ,  Jérôme Giustiniani

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00

Abstract: The present invention relates to monoclonal antibodies that bind to the CD160-TM isoform. The inventors developed new monoclonal antibodies which bind to the CD160-TM isoform but dot not bind to the CD160 GPI-anchored isoform not to the CD160 soluble isoform. In particular, the antibodies of the present invention are suitable for amplifying NK cell activation and therefore cytotoxic functions NK cells.

公开(公告)号：US20190256595A1

公开(公告)日：2019-08-22

申请号：US16343889

申请日：2017-10-25

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PARIS DIDEROT - PARIS 7 ,  UNIVERSITÉ DE MONTPELLIER ,  INSTITUT JEAN GODINOT ,  INSTITUT RÉGIONAL DU CANCER DE MONTPELLIER

Inventor： Armand BENSUSSAN ,  Bruno ROBERT ,  Pierre MARTINEAU ,  Myriam CHENTOUF ,  Anne MARIE-CARDINE ,  Jérôme GIUSTINIANI

IPC: C07K16/28

Abstract: The present invention relates to monoclonal antibodies that bind to the CD160-TM isoform. The inventors developed new monoclonal antibodies which bind to the CD160-TM isoform but dot not bind to the CD160 GPI-anchored isoform not to the CD160 soluble isoform. In particular, the antibodies of the present invention are suitable for amplifying NK cell activation and therefore cytotoxic functions NK cells.

公开(公告)号：US20190151346A1

公开(公告)日：2019-05-23

申请号：US16300233

申请日：2017-05-09

Applicant: INSERM (INSTITUTE NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITE PARIS DIDEROT - PARIS 7 ,  OREGA BIOTECH ,  INSTITUT JEAN GODINOT

Inventor： Reem AL-DACCAK ,  Jérôme GIUSTINIANI ,  Jérémy BASTID ,  Armand BENSUSSAN ,  Yacine MERROUCHE ,  Christian GARBAR

IPC: A61K31/713 ,  C07K16/24 ,  C07K16/28 ,  A61P35/00 ,  C12N15/113

Abstract: The present invention relates to combinations therapies for the treatment of cancer. In particular the present invention relates to a method for enhancing the potency of an HER inhibitor administered to a patient as part of a treatment regimen, the method comprising administering to the patient a pharmaceutically effective amount of an IL-17B or IL-17E inhibitor in combination with the HER inhibitor.

公开(公告)号：US20180214550A1

公开(公告)日：2018-08-02

申请号：US15741944

申请日：2016-07-07

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ PARIS DIDEROT - PARIS 7 ,  ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) ,  INSTITUT JEAN GODINOT

Inventor： Armand BENSUSSAN ,  Martine BAGOT ,  Jérôme GIUSTINIANI ,  Yacine MERROUCHE ,  Adèle DE MASSON ,  Anne MARIE-CARDINE

IPC: A61K39/395 ,  A61K39/39 ,  C07K16/28

CPC classification number: A61K39/39566 ,  A61K39/39 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/572 ,  C07K16/2896 ,  C07K2317/31

Abstract: The present disclosure relates to methods and pharmaceutical compositions for enhancing NK cell killing activities. In particular, the disclosure relates to a method of enhancing NK cell killing activities in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound capable of stimulating CD245 on NK cells.